Literature DB >> 7035034

Suppression of in vitro antibody response of human peripheral blood lymphocytes by a heat-labile factor in normal human serum.

M A Aldo-Benson, B H Petersen, M D Benson.   

Abstract

When fresh autologous serum was added to normal human peripheral blood lymphocytes (PBL), it suppressed greater than 90% of the in vitro anti-SRBC response of these cells. Heating the serum for 30 min at 56 degrees C reversed this suppression, Serum from a patient with rheumatoid arthritis and circulating immune complexes had no suppressive effect on the anti-SRBC response of normal human PBL, but serum from patients having the same disease, without circulating immune complexes, did suppress over 90% of the plaque-forming cell response. Serum from an agammaglobulinaemic patient was also suppressive. Addition of serum from patients with congenital deficiencies of C2, C3, C5 and C8 also has a suppressive effect. Absorption of normal serum with immune complexes markedly decreased levels of C1 and C4, and also reversed the suppressive effect of this serum. These data suggest that a heat-labile factor in normal human serum which can be absorbed by immune complexes suppresses the antibody response to a T-dependent antigen. Other immune suppressors found in normal human serum are heat-stable or do not suppress in the presence of normal serum proteins. Thus the suppressive protein described in these studies may be unique. It is possible that either C1 or C4 or both may play a role in the suppression noted here.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7035034      PMCID: PMC1537305     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  Ability of large doses of an alpha-2 plasma protein fraction to inhibit antibody production.

Authors:  J F MOWBRAY
Journal:  Immunology       Date:  1963-05       Impact factor: 7.397

2.  The suppressive effect of a supernate from concanavalin A-activated human lymphocytes: effects of concanavalin A-activated lymphocytes and their supernates on cytotoxic and mixed lymphocyte reactions.

Authors:  D B Kaufman; C Carnaud; J L Stach; J F Bach
Journal:  Cell Immunol       Date:  1979-09-15       Impact factor: 4.868

3.  Regulatory serum lipoproteins: regulation of lymphocyte stimulation by a species of low density lipoprotein.

Authors:  L K Curtiss; T S Edgington
Journal:  J Immunol       Date:  1976-05       Impact factor: 5.422

4.  Inhibition of antibody production by ribonucleases.

Authors:  J F Mowbray; J Scholand
Journal:  Immunology       Date:  1966-11       Impact factor: 7.397

5.  Cellular immunity in the mouse. I. In vitro lymphocyte reactivity.

Authors:  S M Phillips; C B Carpenter; J P Merrill
Journal:  Cell Immunol       Date:  1972-10       Impact factor: 4.868

6.  Serum factors affecting the incorporation of (3H)thymidine by lymphocytes stimulated by antigen. 3. Evidence for a role of complement from studies with specific complement inhibitors.

Authors:  D R Forsdyke
Journal:  Immunology       Date:  1973-10       Impact factor: 7.397

7.  Effects of human alpha-foetoprotein on human B and T lymphocyte proliferation in vitro.

Authors:  R A Murgita; L C Andersson; M S Sherman; H Bennich; H Wigzell
Journal:  Clin Exp Immunol       Date:  1978-08       Impact factor: 4.330

8.  Immunostimulatory and immunosuppressive factors in human cancer ascites fluids: effect on the primary plaque-forming response in vitro.

Authors:  A M Badger; V J Merluzzi; S R Cooperband
Journal:  Cell Immunol       Date:  1976-11       Impact factor: 4.868

9.  Studies on immunosuppression by cobra venom factor. II. On responses to DNP-Ficoll and DNP-Polyacrylamide.

Authors:  T Matsuda; G P Martinelli; A G Osler
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

10.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.